NCT07671417 Imaging Study in Metastatic Clear Cell RCC.
| NCT ID | NCT07671417 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | RayzeBio, Inc. |
| Condition | Metastatic Clear Cell Renal Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-06-15 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 10 participants in total. It began in 2026-06-15 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).
Eligibility Criteria
Inclusion Criteria: * At least 18 years old at the time of signing the informed consent form (ICF). * Biopsy proven metastatic clear cell renal cell carcinoma (RCC) Exclusion Criteria: * Subjects taking below mentioned medications that cannot be stopped 5 half-lives prior to RYZ512 administration and cannot be restarted until all study-related imaging is completed: Anticonvulsants, Antipsychotics, Carbonic Anhydrase inhibitors, COX-2 Inhibitors, Sulfatase Inhibitors, Sulfonamides * Women of Childbearing Potential that are pregnant or breastfeeding. Note: Additional criteria may apply and will be assessed by the study site
Contact & Investigator
Freddy Escorcia, MD, PhD
STUDY DIRECTOR
RayzeBio, Inc.
Frequently Asked Questions
Who can join the NCT07671417 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Clear Cell Renal Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07671417 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07671417 currently recruiting?
Yes, NCT07671417 is actively recruiting participants. Contact the research team at clinicaltrials@rayzebio.com for enrollment information.
Where is the NCT07671417 trial being conducted?
This trial is being conducted at Saint Leonards, Australia, Nedlands, Australia, Perth, Australia, Christchurch, New Zealand and 2 additional locations.
Who is sponsoring the NCT07671417 clinical trial?
NCT07671417 is sponsored by RayzeBio, Inc.. The principal investigator is Freddy Escorcia, MD, PhD at RayzeBio, Inc.. The trial plans to enroll 10 participants.